In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Impacting millions of children in the U.S. alone, asthma can be particularly problematic to diagnose with specificity — ...

Iconovo deal aims to identify the deal product properties concerning particle size, stability, and device compatibility.

Iconovo AB, a developer of inhalable drugs based on proprietary inhalers and dry powder formulations, and Lonza, a healthcare ...

When designing and developing electronic medical devices for users who may be in pain, under duress, or untrained, the goal ...

Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRx™, today announced the ...

Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). The GoResp ...

Inhaled insulin was noninferior to usual care in glycemic control outcomes after 17 weeks among patients with type 1 diabetes.

"We felt we needed to do something in Rachel's memory and if we can save a life we've done, and Rachel has done, something to ...

A 36-year-old Hopkins mother has been sentenced to over three years in prison for second-degree manslaughter in the death of ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...